This company listing is no longer active
NuGenerex Immuno-Oncology Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on NuGenerex Immuno-Oncology's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Apr 2021 |
Recent past performance updates
No updates
Recent updates
No updates
In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, NuGenerex Immuno-Oncology has not provided sufficient past data to assess its track record.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.
Show sectionRevenue & Expenses Breakdown
How NuGenerex Immuno-Oncology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Apr 21 | 0 | -6 | 2 | 3 |
| 31 Jan 21 | 0 | -5 | 1 | 2 |
| 31 Oct 20 | 0 | -3 | 1 | 1 |
| 31 Jul 20 | 0 | -2 | 0 | 0 |
| 30 Apr 20 | 0 | -1 | 0 | 0 |
| 31 Jan 20 | 0 | -1 | 0 | 0 |
| 31 Oct 19 | 0 | -1 | 0 | 0 |
| 31 Jul 19 | 0 | -1 | 0 | 0 |
| 31 Jul 18 | 1 | 0 | 0 | 0 |
Quality Earnings: Insufficient data to determine if NUGX has high quality earnings.
Growing Profit Margin: Insufficient data to determine if NUGX's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if NUGX's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare NUGX's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if NUGX's earnings growth over the past year exceeded the Pharmaceuticals industry average.
Return on Equity
High ROE: NUGX has a negative Return on Equity (0%), as it is currently unprofitable.